22,500 Bristol Myers Squibb Company $BMY Shares Sold by Axiom Investment Management LLC

Axiom Investment Management LLC trimmed its stake in Bristol Myers Squibb Company (NYSE:BMY) by 96.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 792 shares of the biopharmaceutical company’s stock after selling 22,500 shares during the period. Axiom Investment Management LLC’s holdings in Bristol Myers Squibb were worth $49,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Pictet Asset Management Holding SA grew its stake in shares of Bristol Myers Squibb by 0.4% during the 3rd quarter. Pictet Asset Management Holding SA now owns 2,035,236 shares of the biopharmaceutical company’s stock valued at $127,002,000 after acquiring an additional 8,549 shares during the period. Leelyn Smith LLC raised its stake in Bristol Myers Squibb by 0.8% during the 3rd quarter. Leelyn Smith LLC now owns 59,776 shares of the biopharmaceutical company’s stock worth $3,730,000 after acquiring an additional 464 shares during the period. Pegasus Asset Management Inc. bought a new stake in Bristol Myers Squibb during the 3rd quarter worth approximately $225,000. May Hill Capital LLC raised its stake in Bristol Myers Squibb by 13.3% during the 3rd quarter. May Hill Capital LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $268,000 after acquiring an additional 503 shares during the period. Finally, Alps Advisors Inc. lifted its holdings in Bristol Myers Squibb by 13.2% during the third quarter. Alps Advisors Inc. now owns 632,070 shares of the biopharmaceutical company’s stock valued at $39,441,000 after purchasing an additional 73,806 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
• Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
• Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
• Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
• Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Insider Activity at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Julia A. Haller sold 3,800 shares of the business’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the transaction, the director directly owned 30,279 shares in the company, valued at $1,916,963.49. This trade represents a 11.15% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.05% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Daiwa Securities Group upped their price target on shares of Bristol Myers Squibb from $53.00 to $66.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Guggenheim restated a “buy” rating and set a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Roth Capital assumed coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “buy” rating and a $75.00 price objective on the stock. UBS Group cut shares of Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 5th. Finally, HSBC reaffirmed a “hold” rating and issued a $65.00 target price (up from $60.00) on shares of Bristol Myers Squibb in a report on Thursday, September 10th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Hold” and an average target price of $65.46.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $62.20 on Friday. The stock has a 50-day moving average price of $62.34 and a 200 day moving average price of $60.11. The stock has a market capitalization of $127.15 billion, a P/E ratio of 13.79, a P/E/G ratio of 0.32 and a beta of 0.20. Bristol Myers Squibb Company has a 12-month low of $45.26 and a 12-month high of $68.64. The company has a current ratio of 1.59, a quick ratio of 1.44 and a debt-to-equity ratio of 1.79.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The company had revenue of $13.07 billion for the quarter, compared to analysts’ expectations of $12.72 billion. During the same period in the previous year, the firm earned $1.63 EPS. The firm’s revenue was up 6.9% compared to the same quarter last year. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.45 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were given a dividend of $0.63 per share. The ex-dividend date was Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.88%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.